Objective: To explore the pattern of serum metabolic disorders in patients with immunoglobulin anephropathy (IgAN) from the perspective of metabolism through non-targeted metabolomics, and to analyze the important metabolites involved in the occurrence and development of IgAN. Methods: Non-targeted metabolomics analysis was conducted on serum samples from 15 patients with IgAN and 15 healthy controls from the First Affiliated Hospital of Baotou Medical College to screen for differential metabolites. Pathway analysis was also performed to reveal the critical metabolic pathways in IgAN. Additionally, the correlations between IgAN metabolites, as well as between metabolites and clinicopathological features were explored to clarify the significance of metabolites in IgAN. Results: (1) There were significant differences in serum metabolites between IgAN patients and healthy controls. Twenty key metabolites including amino acids, uremic toxins and fatty acids, as well as five differential metabolic pathways including tryptophan metabolism, phenylalanine and tyrosine metabolism, citric acid cycle, ketone body metabolism and carnitine synthesis pathway were found, which were helpful to further understand the metabolic network of IgAN. (2)The metabolic pathway significantly associated with IgAN was the metabolism of aromatic amino acids (ie, phenylalanine, tyrosine and tryptophan). (3) There was a significant correlation between differential metabolites and clinical indicators of IgAN patients. The changes of metabolites were related to segmental glomerulosclerosis and increased mesangial cells. Conclusion: The changes of serum metabolites in IgAN patients are involved in the occurrence and development of IgAN.
SONG Jixuan
,
MI Yan
,
ZHANG Min
,
WU Chengdong
,
WANG Caili
. Exploration of metabolites involved in the occurrence and development of IgA nephropathy based on non-targeted metabolomics exploration of metabolites[J]. Journal of Baotou Medical College, 2025
, 41(8)
: 28
-35
.
DOI: 10.16833/j.cnki.jbmc.2025.08.006
[1] McGrogan A, Franssen CFM, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature[J]. Nephrol Dial Transplant, 2011, 26(2): 414-430.
[2] Schena FP, Nistor I. Epidemiology of IgA nephropathy: a global perspective[J]. Semin Nephrol, 2018, 38(5): 435-442.
[3] Pattrapornpisut P, Avila-Casado C, Reich HN. IgA Nephropathy: Core Curriculum 2021[J]. Am J Kidney Dis, 2021, 78(3): 429-441.
[4] Magistroni R, D'Agati VD, Appel GB, et al. New developments in the genetics, pathogenesis, and therapy of IgA nephropathy[J]. Kidney Int, 2015, 88(5): 974-989.
[5] Kidney Disease. Improving global outcomes (KDIGO) glomerular diseases work group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases[J]. Kidney Int, 2021, 100(4S): S1-S276.
[6] Park S, Lee J, Yang SH, et al. Comprehensive metabolomic profiling in early IgA nephropathy patients reveals urine glycine as a prognostic biomarker[J]. J Cell Mol Med, 2021, 25(11): 5177-5190.
[7] Trimarchi H, Barratt J, Cattran DC, et al. Oxford classification of IgA nephropathy 2016: an update from the iga nephropathy classification working group[J]. Kidney Int, 2017, 91(5): 1014-1021.
[8] Cervenka I, Agudelo LZ, Ruas JL. Kynurenines: tryptophan's metabolites in exercise, inflammation, and mental health[J]. Science, 2017, 357(6349): eaaf9794.
[9] Venkatesh M, Mukherjee S, Wang H, et al. Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and Toll-like receptor 4[J]. Immunity, 2014, 41(2): 296-310.
[10] Wu HW, Tang DE, Yun MH, et al. Metabolic dysfunctions of intestinal fatty acids and tryptophan reveal immuno-inflammatory response activation in iga nephropathy[J]. Front Med (Lausanne), 2022, 9: 811526.
[11] Ramezani A, Massy ZA, Meijers B, et al. Role of the gut microbiome in uremia: a potential therapeutic target[J]. Am J Kidney Dis, 2016, 67(3): 483-498.
[12] Lin CJ, Wu V, Wu PC, et al. Meta-analysis of the associations of p-cresyl sulfate (PCS) and indoxyl sulfate (IS) with cardiovascular events and all-cause mortality in patients with chronic renal failure[J]. PloS one, 2015, 10(7): e0132589.
[13] Xu KY, Xia GH, Lu JQ, et al. Impaired renal function and dysbiosis of gut microbiota contribute to increased trimethylamine-N-oxide in chronic kidney disease patients[J]. Sci Rep, 2017, 7(1): 1445.
[14] Sui W, Li L, Che W, et al. A proton nuclear magnetic resonance-based metabonomics study of metabolic profiling in immunoglobulin a nephropathy[J]. Clinics (Sao Paulo), 2012, 67(4): 363-373.
[15] Kalantari S, Nafar M, Samavat S, et al. 1 H NMR-based metabolomics study for identifying urinary biomarkers and perturbed metabolic pathways associated with severity of IgA nephropathy: a pilot study[J]. Magn Reson Chem, 2017, 55(8): 693-699.
[16] Burns JL, Nakamura MT, Ma DWL. Differentiating the biological effects of linoleic acid from arachidonic acid in health and disease[J]. Prostaglandins Leukot Essent Fatty Acids, 2018, 135: 1-4.
[17] Tajima T, Yoshifuji A, Matsui A, et al. β-hydroxybutyrate attenuates renal ischemia-reperfusion injury through its anti-pyroptotic effects[J]. Kidney Int, 2019, 95(5): 1120-1137.
[18] Gao XF, Chen WJ, Li RX, et al. Systematic variations associated with renal disease uncovered by parallel metabolomics of urine and serum[J]. BMC Syst Biol, 2012, 6 Suppl 1(Suppl 1): S14.
